- Home
- XFOR vs LNZA Comparison
XFOR vs LNZA Comparison
Compare XFOR & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- LNZA
- Stock Information
- Founded
- XFOR 2014
- LNZA 2005
- Country
- XFOR United States
- LNZA United States
- Employees
- XFOR N/A
- LNZA N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- LNZA Major Chemicals
- Sector
- XFOR Health Care
- LNZA Industrials
- Exchange
- XFOR Nasdaq
- LNZA Nasdaq
- Market Cap
- XFOR 84.3M
- LNZA 98.1M
- IPO Year
- XFOR N/A
- LNZA N/A
- Fundamental
- Price
- XFOR $3.42
- LNZA $24.38
- Analyst Decision
- XFOR Strong Buy
- LNZA Hold
- Analyst Count
- XFOR 3
- LNZA 2
- Target Price
- XFOR $34.17
- LNZA $200.00
- AVG Volume (30 Days)
- XFOR 412.4K
- LNZA 27.8K
- Earning Date
- XFOR 11-12-2025
- LNZA 11-07-2025
- Dividend Yield
- XFOR N/A
- LNZA N/A
- EPS Growth
- XFOR N/A
- LNZA N/A
- EPS
- XFOR N/A
- LNZA N/A
- Revenue
- XFOR $32,774,000.00
- LNZA $40,540,000.00
- Revenue This Year
- XFOR $1,307.51
- LNZA N/A
- Revenue Next Year
- XFOR N/A
- LNZA $86.24
- P/E Ratio
- XFOR N/A
- LNZA N/A
- Revenue Growth
- XFOR 5721.31
- LNZA N/A
- 52 Week Low
- XFOR $1.35
- LNZA $14.01
- 52 Week High
- XFOR $26.83
- LNZA $274.00
- Technical
- Relative Strength Index (RSI)
- XFOR 52.78
- LNZA 60.49
- Support Level
- XFOR $3.35
- LNZA $22.01
- Resistance Level
- XFOR $3.63
- LNZA $25.93
- Average True Range (ATR)
- XFOR 0.31
- LNZA 3.66
- MACD
- XFOR -0.03
- LNZA -0.34
- Stochastic Oscillator
- XFOR 61.97
- LNZA 58.41
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.